Livzon Pharmaceutical Group Inc. (01513) published its Monthly Return for the period ended 31 January 2026. According to the announcement, the authorized share capital of H shares and A shares remained at RMB 299,807,117 and RMB 588,100,054 respectively, maintaining a total of RMB 887,907,171.
As of the end of January 2026, the company’s H shares in issue stood at 299,807,117, while A shares totaled 588,100,054. The H share public float requirement was confirmed to be in compliance. No new share options, warrants, convertibles, or other share issuance agreements were disclosed for January.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.